2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2538 Allogeneic transplantation improves survival in TP53-mutated AML in both single-hit and double-hit disease

David M. Mueller, MD, Sharon Santhosh, MD2, Adit Singhal, MD, MS3, David W Chitty, MD4, Kelli Cole5, Ruthee Bayer, MD6, Jaime Andres Suarez-londono, MD7, Douglas E Gladstone, MD8, Stephanie Boisclair, MD9
1 Northwell Health, New Hyde Park, New York, United States
2 Northwell Health, New Hyde Park, New York, United States
3 Northwell Health, New Hyde Park, New York, United States
4 Northwell Health, New Hyde Park, New York, United States
5 Northwell Health, New Hyde Park, New York, United States
6 Northwell Health, New Hyde Park, New York, United States
7 Northwell Health, New Hyde Park, New York, United States
8 Northwell Health, New Hyde Park, New York, United States
9 Northwell Health, New Hyde Park, New York, United States
Background: 
The role for allogeneic transplantation (allo-HSCT) in the management of TP53-mutated AML remains unclear. Without transplant, outcomes are dismal. TP53-mutated AML can be categorized as single-hit (SH) or double-hit (DH) as an approximation for allelic status. The impact of TP53 allelic status on transplant outcomes is not well defined. We evaluated allo-HSCT utilization and outcomes across TP53 allelic subgroups.

Methods: 
Cases of TP53-mutated AML diagnosed 1/2019 to 7/2025 were analyzed. TP53-mutated AML, defined by a TP53 mutation (VAF ≥2%), 17p cytogenetic abnormality, or both, was classified per Grob et al., 2022. DH was defined as ≥2 TP53 mutations, a TP53 mutation with 17p abnormality, or a single mutation with VAF >55%. To reduce immortal-time bias inherent to transplant timing, comparisons of transplanted versus non-transplanted patients were restricted to those who achieved a morphologic leukemia-free state (MLFS) and remained alive ≥4 months, the median time to transplant. Post-transplant outcomes were analyzed from day 0, whereas survival comparisons were measured from first MLFS. Overall survival (OS) and relapse-free survival (RFS) were estimated by Kaplan–Meier methods. Estimated cumulative incidences (ECI) were calculated using competing-risks methods with Gray’s test.

Results: 
A total of 113 TP53-mutated AML patients were identified (median age 71.3 years); 26.5% were SH, 61.9% were DH, and 11.5% were unclassifiable. Most had de novo AML (56.6%) and received HMA±venetoclax induction (63.7%). Of classifiable patients, 53 achieved MLFS and 23 underwent allo-HSCT in first remission. Of those that underwent allo-HSCT (of any hit status), median OS, RFS, and GVHD- and relapse-free survival (GRFS) from transplant were 12.4 mo (6.16–NR), 12 mo (3.4–NR), and 8.3 mo (4–21.4), respectively.The 1-year ECI of grade II–IV acute GVHD was 27.1% with no grade III–IV events; the 2-year ECI of moderate/severe chronic GVHD was 9.1%. Patients who developed GVHD of any grade (n=9) had improved 2-year OS (76.2% vs 25.4%; p=0.006) and RFS (76.2% vs 23.4%; p=0.004). One-year ECI of relapse and NRM were 27% and 8.7%. There was no difference in OS, RFS, or GRFS by conditioning intensity, donor source, or GVHD prophylaxis regimen. In the MLFS-eligible cohort, allo-HSCT was associated with significantly improved OS (17.7 vs 10.0 mo; p=0.0045) and RFS (19.2 vs 9.2 mo; p=0.0005) compared with non-transplanted patients. This benefit was present in both SH and DH groups: each demonstrated improved OS and RFS with allo-HSCT. Within the allo-HSCT cohort, SH patients had longer OS (81.2 vs 12.3 mo) and RFS (81.2 vs 8.3 mo) than DH patients, though differences were not statistically significant (OS p=0.29; RFS p=0.43). SH and DH groups were similar in ECIs of relapse, NRM, and incidence of acute or chronic GVHD. Three DH patients with Day +60 MRD positivity received HMA maintenance.

Conclusion: 
Allo-HSCT was associated with a significant OS and RFS advantage in TP53-mutated AML patients who achieved MLFS and remained transplant-eligible. This benefit was observed in both SH and DH disease. These findings support offering allo-HSCT to appropriately selected TP53-mutated AML patients who achieve MLFS, irrespective of hit status, and highlight the need for validation in larger prospective cohorts.
David M. Mueller, MD: No relevant conflicts of interest to declare.